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Edited by Amy McGoughAbstract The solution structure of the human p47 SEP domain
in a construct comprising residues G1-S2-p47(171–270) was
determined by NMR spectroscopy. A structure-derived hypoth-
esis about the domains’ function was formulated and pursued in
binding experiments with cysteine proteases. The SEP domain
was found to be a reversible competitive inhibitor of cathepsin L
with a Ki of 1.5 lM. The binding of G1-S2-p47(171–270) to
cathepsin L was mapped by biochemical assays and the binding
interface was investigated by NMR chemical shift perturbation
experiments.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Protein structure1. Introduction
AAA-type ATPases (ATPases associated with various cel-
lular activities) and their binding partners form protein sys-
tems involved in the regulation of membrane fusion [1],
postmitotic reassembly of the Golgi apparatus, ubiquitin-
related processes and DNA replication. p97 is a member of this
family, which includes the Clp family proteins and yeast
CDC48 [2]. It forms a hexameric structure and contains two
ATPase domains, belonging thus to the AAA+ superfamily.
p97 binds a variety of proteins with various functions, for
example VCIP135 (valosin-containing protein (p97)/p47 com-
plex-interacting protein p135) [3] and p47. It is composed of
three domains: an N-terminal domain N, which binds the
conserved 370 residue eukaryotic adaptor protein p47 [2] fol-* Corresponding author. Fax: +493094793169.
E-mail address: oschkinat@fmp-berlin.de (H. Oschkinat).
1 Present address: Structural Genomics Consortium, University of
Oxford, Botnar Research Centre, OX37LD, UK.
Abbreviations: NaPi, sodium phosphate buﬀer; SEP, Saccharomyces
cerevisiae SHP1, Drosophila melanogaster eyes closed gene, vertebrate
p47; NOE, nuclear Overhauser eﬀect; CSP, chemical shift perturba-
tions
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doi:10.1016/j.febslet.2004.09.037lowed by two ATPase binding domains called D1 and D2.
Binding of p47 to p97 activates the ubiquitin-binding site in
p47 and deactivates the ATPase activity of p97. Like many
adaptor proteins, p47 is also characterised by a modular
composition, comprising an N-terminal UBA domain [4,5], a
SEP (Saccharomyces cerevisiae, Drosophila melanogaster eyes
closed gene and vertebrate p47) domain and a C-terminal
UBX domain. The latter consists of about 80 amino acids and
adopts a ubiquitin-like-b grasp fold [6]. p47 binds to p97 by
insertion of a conserved loop of its UBX domain into a hy-
drophobic pocket within the p97 N domain [2].
As yet unknown is the function of the SEP domain, which
occurs frequently and mainly in single units. The co-occur-
rence of SEP and UBX domains in evolutionarily conserved
combinations is also interesting. Almost all proteins contain-
ing a SEP domain are succeeded closely by a UBX domain,
according to SMART [7]. The solution structure of the SEP
domain from rat p47 using a construct containing residues
171–246 was recently determined by Yuan et al. [8]. It was
suggested that the SEP domain is involved in the binding of
p47 to p97 [8]. Here, we present the structure of the human p47
SEP domain, using an extended construct (residues 171–270).
Furthermore, we have derived a novel, structure-based hy-
pothesis about the function of the p47 SEP domain, impli-
cating it as a reversible competitive inhibitor of the lysosomal
cysteine protease cathepsin L. The binding interface of the SEP
domain was investigated by NMR.2. Materials and methods
2.1. Expression/puriﬁcation
The DNA sequence encoding human p47(171–270) SEP domain
(NM 016143) was cloned from a human foetal brain cDNA expression
library (hEx1) [9] into the expression plasmid pQTEV (GenBank Ac-
cession No. AY243506). Construct residues 3–102 correspond to se-
quence positions 171–270 from human p47. Two N-terminal residues
from the cloning site are referred to as G1 and S2. The SEP domain
was expressed as His-tagged-fusion protein in Escherichia coli and
puriﬁed on a MC-Poros column (Applied Biosystems) loaded with
Ni2þ. The His tag was cleaved using TEV protease, at 4 C, overnight.
The untagged SEP domain was further puriﬁed by a ﬁnal gel ﬁltration
step. Uniformly 15N- and 13C/15N-labelled samples of the p47 SEPblished by Elsevier B.V. All rights reserved.
Table 1
Structural statistics of the ensemble
Restraints
ARIA output assignment for NOEs
Unambiguous assignments 1570
Intra-residue 637
Sequential 330
Medium-range 165
Long-range 438
Ambiguous assignments 567
Others
Manually assigned NOEs 113
H-Bonds (from NOE pattern) 18
Dihedrals ( from NOE pattern and JHNHA
experiments )
19
Quality of the ensemble for 20 calculated structures
RMSD (for residues 179-244): from MOLMOL
Backbone atoms 1.04 0.24 A
Side chain heavy atoms 1.75 0.27 A
Violations:
Distances >0.4 A 0
Dihedrals > 5 0
Ramachandran plot: (from PROCHECK NMR)
Most favoured regions 80.9%
Additionally allowed regions 15.2%
Generously allowed regions 2.2%
Disallowed regions 1.8%
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either 0.5 g/l 15NH4Cl or 0.5 g/l
15NH4Cl and 2 g/l
13C glucose, re-
spectively. Deuterated 15N-labelled protein was prepared by growing
cells in 99.8% D2O, using non-deuterated glucose.
2.2. NMR spectroscopy/structure calculation
All NMR spectra were acquired at 300 K and recorded on a Bruker
DRX 600 MHz spectrometer equipped with a cryoprobe, using the
programs PASTE and PAPST [10], except for the 15N-edited-HSQC
which was recorded on a Bruker DMX 750 MHz spectrometer. Uni-
formly 15N-, 13C- and 15N-labelled proteins with concentrations of 1
and 2 mM, respectively, in a buﬀer consisting of 20 mM sodium
phosphate buﬀer (NaPi), 150 mM NaCl and 0.02% NaN3 at pH 5.6 in
90% H2O/10% D2O were used for the experiments. Spectra were
processed using the XWINNMR software (Bruker Biospin). For
backbone assignments, a complete series of 2D side chain-selective
experiments [11] and 3D triple resonance CBCA(CO)NH/CBCANH
and HA(CACO)NH/HA(CA)NH spectra were used [12]. Side chain
resonances were identiﬁed from 3D HBHA(CO)NH, H(CCCO)NH-
TOCSY and (H)CC(CO)NH-TOCSY experiments in H2O. Inter-
proton distances for structure calculation were derived from a 2D
NOESY (mixing time 60 ms), a 3D 15N NOESY–HSQC (80 ms) both
in 90% H2O/10% D2O, and a 3D
13C HMQC–NOESY (80 ms) spec-
trum in 100% D2O [12]. The SPARKY software was used for assign-
ment [13].
15N T1 and T2 relaxation data were measured as described previ-
ously [12]. Both T1 and T2 relaxation times were extracted from two
series comprising each of 11 spectra with relaxation delays of 12, 52,
102, 152, 202, 302, 402, 602, 902, 2002 and 5002 ms for T1 measure-
ments and 6, 10, 18, 26, 34, 42, 82, 122, 162, 202 and 242 ms for T2
measurements. Heteronuclear 1H–15N nuclear Overhauser eﬀect
(NOE) experiments were also recorded. Structures were calculated
with the program ARIA 1.2 [14] using 113 manually assigned NOEs
representing secondary structure NOE patterns, 18 hydrogen bonds
and 19 dihedral angles derived from JHNHA-modulated HMQC ex-
periments [15]. After water reﬁnement, the ﬁnal ensemble was analysed
by MOLMOL [16] and PROCHECK-NMR [17].
2.3. Kinetic binding experiments with cathepsins B, X and L
Human cathepsins B and X were expressed and puriﬁed as described
previously [18,19]. The cDNA for human procathepsin L was ampli-
ﬁed by PCR from a human placenta cDNA library (BD Biosciences
Clontech, Palo Alto, CA) using gene-speciﬁc primers 50-CCGC-
TCGAGAAAAGAGAGGCTGAAGCTACTCTAACATTTGATC-
ACAGTTT-30and 50-ATTTGCGGCCGCTCACACAGTGGGGTA-
GCTGG-30 and Expand DNA polymerase (Roche Applied Science,
Mannheim, Germany). Cathepsin L was expressed and puriﬁed ac-
cording to the procedure described for cathepsin B [18]. Kinetic ex-
periments were performed as previously described [18]. Fluorescence
was monitored on a SPEX FluoroMax spectroﬂuorometer (Jobin
Yvon, Edison, NJ). All kinetic measurements were performed at 25C
in the presence of 50 mM sodium citrate, 1 mM EDTA, 2 mM DTT,
0.2 M NaCl and 3% DMSO. The assays for cathepsins B and L were
carried out at pH 5.5 using the substrate carbobenzoxy-L-phenylala-
nyl-L-arginine-4-methylcoumarinyl-7-amide (Cbz-FR-MCA), for ca-
thepsin X at pH 5.0 as described previously [19]. Inhibition studies
were performed by measuring the steady-state rate of substrate hy-
drolysis (v0) in the presence of G1-S2-p47(171–270). The type of in-
hibition and Ki values were determined by Dixon plot analysis, i.e.,
linear regression of reciprocal plots of the reaction rate (1/v0 vs. [I]) at
varying concentrations of substrate [20]. Statistical analyses were
performed using the GraphPad Prism software (San Diego, CA).
2.4. NMR chemical shift mapping experiments with cathepsin L
A deuterated, 15N-labelled sample of the SEP domain was prepared
for interaction studies with unlabelled inactivated cathepsin L (see
Section 2.1). Both proteins were dialysed against the same buﬀer
comprising 20 mM NaPi, 50 mM NaCl and 100 lM methyl meth-
anethiosulfonate at pH 5.6 in 90% H2O/10% D2O. A
15N HSQC
spectrum was recorded immediately after addition of cathepsin L to
the SEP domain using a Bruker DRX 600 MHz spectrometer equipped
with a cryoprobe. Protein concentrations were kept minimal and the
experimental temperature was kept low at 278 K to slow down the
rapid proteolytic cleavage of the SEP domain construct which oc-
curred at higher temperatures and protease concentrations. Finalconcentrations were 50 lM for the SEP domain and 10 lM for ca-
thepsin L, respectively. Chemical shift perturbations were analysed
using Sparky version 3.69.3. Results and discussion
3.1. Solution structure of the human p47 SEP domain
A construct comprising residues G1-S2-p47(171–270) was
used for structure determination by NMR. Resonance as-
signments were obtained for 13C, 15N and 1H nuclei in all
residues except for G1 and S2. The proton side chain reso-
nances of Q174 and the aromatic 13C, 1H resonances of F249
and F252 could not be assigned. Structures were calculated
using ARIA 1.2 [14] and reﬁned iteratively by manual in-
spection of the NOESY spectra and repeated structure calcu-
lations. The ﬁnal structures were based on approximately 1570
unambiguously assigned constraints, 18 hydrogen bonds and
19 dihedral angles derived from speciﬁc NOE patterns and
JHNHA-modulated experiments (Table 1).
The structure of the human p47 SEP domain construct
(Figs. 1B and 2A) comprises a b-sheet composed of four
strands (residues 180–187 (b1), 191–193 (b2), 198–200 (b3)
231–237 (b4)), and two a-helices (residues 207–215 (a1), 220–
224 (a2)). One side of the b-sheet faces a1 and a2. The latter
touches the end of b4 and b1 at the edge of the domain, ar-
ranged in a 90 angle with respect to a1. The hydrophobic core
comprises residues V180, L184, L186, W187, F191, L193,
L198, Y201, F209, L210, I213, L223, L225, V231, L233, M235
and F243. Only a small number of NOE distance restraints
were observed for residues preceding D179 and following
V244. The protein was well structured from residues D179 to
V244. Residues more than 80% conserved in a non-redundant
alignment of all SEP domains present in the SMART database
are labelled green and black. The green-labelled residues L210,
F209, F191, L198, W187 and F243 are located in a diagonal
plane through the SEP domain, close to the loops between b1
Fig. 1. (A) Multiple sequence alignment of selected SEP domains. The secondary structure is shown on top of the investigated SEP domain construct.
The ﬁrst two residues G1–S2 are not shown. Swissprot accession numbers from top to bottom: Q9UNZ2, O35987, Q9CZ44, P34223, Q8T4C3,
Q8RWU7, Q9N2W5. The ruler (r) starts at position 180 followed by 190, etc. (B) Ensemble of 10 lowest energy solution structures of the human p47
SEP domain. In green and black are the side chains of residues which are more than 80% conserved. Residues D203, P204 and N206 are found in a
loop above a cross-sectional plane comprised by residues L210, F209, F191, L198, W187 and F243. Structural ﬁgures were generated using
MOLMOL [16].
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shown, since it is found at the end of this plane near the ﬂexible
C-terminus. The black-labelled residues D203, P204 and N206
are found on the domain surface in a loop preceding a1 above
the diagonal plane. Residues P219, L222 and V231 lie below
this plane and are mainly involved in hydrophobic contacts
between the b-sheet and a2. Yuan et al. [8] determined recently
the structure of the rat p47 SEP domain (1VAZ). The overall
structure of the human p47 SEP domain is the same but diﬀers
slightly in the orientation of the loop between a2 and b4
(Fig. 2A, highlighted in green). We assigned manually those
NOEs which determine the loop orientation (available upon
request from the authors). Our construct which did not con-
tain a His tag showed NOEs which are indicative of contacts
between the loop a2/b4 and strand b4. The potential binding
site is well-ordered and very similar in both human and rat
structures. The Ca RMSD of two lowest energy structures inthis region (residues 179–195, 198–217 and 233–241) was
1.74 A. Interestingly, no structural diﬀerences are caused by
the three point mutations between the human and rat se-
quences. The mutation S189T is structurally neutral and the
other two mutations appear in the ﬂexible N-terminus.
The distribution of conserved hydrophobic residues and the
calculated lipophilic and electrostatic potentials on the domain
surface are shown in Fig. 2B–D. Residues F191, Y201, P204,
L210, I213, P219, L222, L233 and M235 cover a continuous
area (Fig. 2B, left). The surface on the reverse side (Fig. 2B,
right) shows residues W187 and F243 making up one con-
served area and the loop containing residues D203, P204 and
N206 comprising a second. Residues V180, G196 and F209 are
also shown. The lipophilic potential was calculated for the
accessible surface area according to Heiden et al. [21]. Hy-
drophobic (yellow) and hydrophilic (green) areas are visualised
in Fig. 2C and show sharp contours with cavities suitable for
Fig. 2. (A) Ribbon representations of the human p47 SEP domain. (B–
D) Surface properties of the human p47 SEP domain. The same ori-
entations are used as in (A). (B) Surface exposed loop and conserved
hydrophobic residues are shown in red. (C) Hydrophilic (green) and
hydrophobic (yellow) regions. (D) Electrostatic potential: positive
(blue), negative (red). All surface ﬁgures were made using SYBYL 6.9.
M. Soukenik et al. / FEBS Letters 576 (2004) 358–362 361accommodating the side chains of interaction partners. This
disc shaped pocket is large enough to bury a tryptophan side
chain.
The electrostatic potential of the accessible surface area re-
veals a dipole character of the p47 SEP domain. Fig. 2D shows
an acidic stretch, comprising residues D234, E236 and D237
from b4 and residues D240 and E241 from the C-terminal tail,
on one side of the molecule. The basic residues R214, R215
from helix 1 and R223, R224 from helix 2 create a positive
potential on the opposite side.3.2. Dynamics of the investigated SEP construct
G1-S2-p47(171–270)
The SEP domain boundaries were indicated in the SMART
database as S176 and T270. Despite considerable sequence
homology at the C-terminus, the structured region ends at
V244. To investigate the ﬂexibility of the C-terminus, we de-
termined 15N T1, T2 and heteronuclear NOEs (relaxation data
not shown). The ratio T1/T2 drops signiﬁcantly preceding
residues D179 and following K245. The heteronuclear 1H–15N
NOE measurements showed positive signals for the residues
between D179 and K245, whereas the signals from the ﬂexible
termini were strongly negative. These data show that the N-
terminal (G1-S2-p47(171–178)) and C-terminal (p47(245–270))
tails are therefore ﬂexible in solution. The rotational correla-
tion time sc was determined to be 6.4 ns, indicating a mono-
meric state for the domain under the conditions investigated.
Further experiments involving hydrogen exchange support
the results of the relaxation measurements. After lyophilisation
and redissolving in D2O, we immediately measured
1H–15N
HSQC experiments. Both ﬂexible tails exchanged rapidly with
D2O. Amide protons from the structured regions were pro-
tected to varying extents. After 2 h, 15N-attached protons from
residues 182–187, 190–192, 199, 210–214, 222, 234, 236 and
238, which are located in the core, were not exchanged. In
summary, the data from relaxation experiments and D2O ex-
change, together with the number of assigned NOE restraints
per residue, show the SEP domain to extend from residue
D179 to V244.
3.3. A structure-derived hypothesis: The p47 SEP domain
interacts with cysteine proteases
Neither the activity nor the cellular function of the p47 SEP
domain is known to date. In light of the existing structural
investigations and the biological context, we have developed a
hypothesis based on the structural properties of two loops and
the similarity of the overall structure of the SEP domain to
inhibitors of cysteine proteases [22]. The p47 SEP domain has
two very rigid and well-ordered loops (b1–b2, b3–a1), which
are located close to the conserved residues of the protein core.
The loop between b3 and a1 is particularly highly conserved.
The C-terminus of the domain is close to these two loops, in
particular to the loop connecting b1 and b2. Such arrange-
ments are also seen in inhibitors of cysteine proteases, such as
cystatins and steﬁns [23]. Due to the structural similarity, we
hypothesised that the SEP domain may bind to and inhibit
cysteine proteases.
We therefore investigated the inhibition of three cysteine
proteases, cathepsins L, B and X, by the p47 SEP domain. The
experiments showed clearly that G1-S2-p47(171–270) is a re-
versible competitive inhibitor of cathepsin L with a Ki of
1.5 lM (Fig. 3). Cathepsin B was much more weakly and ca-
thepsin X not at all inhibited at the highest concentration of
the SEP construct used (15 lM). The reduced or absent aﬃnity
of the SEP domain for cathepsins B and X (Ki > 50 lM) is
likely to be due to unfavourable interactions with the occlud-
ing loop in cathepsin B [24] or the mini loop in cathepsin X
[25].
NMR titration experiments were used to map the binding
site between cathepsin L and the 15N-labelled deuterated SEP
domain. In agreement with our hypothesis, we observed
chemical shift perturbations (CSP) for the amide proton and
nitrogen resonances of residues S189 and G190 which are
Fig. 3. Reversible competitive inhibition of human cathepsin L by the
G1-S2-p47(171–270) SEP domain construct. (A) The rate of substrate
hydrolysis (v0) by cathepsin L was measured in the presence of varying
amounts of the SEP domain. The rate of hydrolysis of the substrate
Cbz-FR-MCA (1 lM) by cathepsin L (10 pM) was constant during the
assay (15 min). (B) Dixon plots for the inhibition of cathepsin L by the
SEP domain at 0.5 lM (d), 1 lM (s) and 4 lM (.) of Cbz-FR-MCA.
The Ki was determined from reciprocal plots (1/v0) vs. [I] according to
[20], and calculated to be 1.5 0.2 lM.
362 M. Soukenik et al. / FEBS Letters 576 (2004) 358–362located in the turn between b1 and b2, and for residues Y201,
Q202, D203 and N206 found in the loop following b3. Addi-
tionally, we observed CSP near the ﬂexible C-terminus par-
ticularly for residues F243 and K245. However, we conclude
from the disappearance of the peaks due to F250, K251, T254,
G255, E256, G257, L260, G261 and A264 that the C-terminus
was cleaved.
Substrate-like cleavage of cystatins and reappearance of
enzymatic activity after initial complex formation was previ-
ously described for cathepsin L [26]. Reappearance of enzyme
activity after initial inhibition would result in a sigmoidal
curve. We did not observe such temporary inhibition in the
activity assay, presumably due to the low enzyme concentra-
tions used. However, cleavage of the SEP domain by cathepsin
L could still occur at higher enzyme concentrations or on
prolonged incubation.
In conclusion, p47 may act as a speciﬁc adaptor molecule for
cathepsin L to regulate a yet unidentiﬁed cellular process.
Whether the SEP domain binds to cathepsin L in a chaperone-like manner or inhibits the activity of cathepsin L in vivo re-
mains to be determined.
The structural coordinates have been deposited in the PDB
under accession code 1SS6.
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